Innovative drug development for headache disorders (Frontiers in Headache Research Series, 16)

migraine Treatment Improved Considerably With The Advent Of The 'triptans' In The 1990s. While The Drugs Used Previously For Headache Treatment Had Efficacy, Some Compounds Had Bothersome Side Effects And Their Overuse Could Lead To Severe Complications. In The Early Days Of The Triptans, It Was Widely Presumed That Migraine Was No Longer A Treatment Problem. However, It Has Gradually Been Recognized That A Significant Proportion Of Patients Are Not Responsive To Triptans Or Do Not Tolerate Them. It Is Now Clear That, Even With Effective Treatment, Patients With Frequent Migraine Attacks Are Not Treated Well Exclusively With Acute Medications. This Is Partly Because Patients Are Still Bothered By The Attacks And Partly Because Frequent Intake Of Acute Medication May Result In Medication-overuse Headache. These Problems Have Led To A Renewed Interest In Preventive Migraine Drugs. part Of The Frontiers In Headache Research Series, This Book Summarizes The Several Promising New Avenues For The Development Of Future Drugs For The Treatment Of Migraine, Including Cortical-spreading Depression Inhibition, Nitric Oxide Synthase Inhibition And Calcitonin Gene-related Peptide (cgrp) Receptor Antagonism, As Well As Other Potential Targets. The Book Presents Frontline Knowledge Of These Evolving Modalities As Far As It Is Available In The Public Domain. It Is Hoped That Readers And Their Patients Will Find It Exciting To Learn About All The Novel Possibilities, And Also That The Impressive Research Advances In Migraine Will Lead To Increased Funding, Not Only Of Migraine But Also Of Other Types Of Headache. The human GABA transporter GAT-2 : from cloning to high throughput screening / Bolette Christiansen ... [et al.] Low throughput preclinical models for headache / Peter J. Goadsby Human models : screening models / Messoud Ashina Stricter success criteria, qualitative and quantitative end-points : acute versus prevention trials / Peer Tfelt-Hansen Health-related quality of life and similar end-points / Carl G.H. Dahlöf Clinically relevant designs and outcome measures for acute migraine trials / Michel D. Ferrari and Hille Koppen Effectiveness of different steroid dosage in Tolosa/Hunt syndrome with different phenotypes : some critical points about the new International Headache Society classification / E. Marchioni ... [et al.] Discussion summary : trial methodology / Jes Olesen Inducible nitric oxide synthase and development of new migraine treatments / Boris A. Chizh Mechanisms of cortical spreading depression as targets for migraine therapy / Kevin C. Brennan and Andrew C. Charles Tonabersat / Peter R. Blower and Paul C. Sharpe Discussion summary : nitric oxide and spreading depression modulators / Nabih Ramadan Calcitonin gene-related peptide : relevance for migraine / Jes Olesen and Inger Jansen-Olesen New 5-hydroxytryptamine-related drug targets / Pramod R. Saxena Effect of two novel calcitonin gene-related peptide-binding compounds in a closed cranial window rat model / Louise Juhl ... [et al.] Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment / Jacob Müller Hansen Discussion summary : calcitonin gene-related peptide and 5-hydroxytryptamine modulators / Rigmor Jensen Migraine : from genes to pathophysiology, transgenic mouse models of migraine / Arn M.J.M. van den Maagdenberg KATP channels and migraine / Inger Jansen-Olesen and Kenneth Beri Ploug Antiepileptic drugs and migraine / Michael A. Rogawski Discussion summary : ion channel modulators and antiepileptics / Pramod R. Saxena Innovative drug development for headache disorders : glutamate / Kirk W. Johnson ... [et al.] The modulation of TRPV1 channels by cannabinoid 1 receptors / Beatriz Fioravanti and Todd W. Vanderah Future targets for headache therapy : prostanoids / Christian Waeber Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia : a study in the rat / Cristina Tassorelli ... [et al.].